FDA NewsNewsworthy

Alunbrig a New Treatment Option for Lung Cancer in Patients with ALK Mutation

June 2017 Vol 3 No 3

On April 28, 2017, Alunbrig (brigatinib; from Takeda) became the newest drug to be approved by the FDA for the treatment of metastatic non–small-cell lung cancer (NSCLC) in patients with the ALK mutation whose tumor progressed while receiving crizotinib or patients who cannot use crizotinib. Alunbrig is a kinase inhibitor and comes as pills that are taken orally.

The clinical trial that led to this approval investigated 2 doses of Alunbrig—180 mg and 90 mg; overall, 53% of patients who took the 180-mg tablet had a good response compared with 48% of patients who took the 90-mg tablet, but severe side effects were slightly higher with the higher dose. The recommended starting dose of Alunbrig is 90 mg for the first 7 days; if the patient tolerates this dose, it should be increased to 180 mg.

The most common side effects reported with the 180-mg dose were nausea, diarrhea, fatigue, cough, and headache. Serious side effects occurred in 38% of patients taking the 90-mg tablet and in 40% of patients taking the 180-mg tablet. Pneumonia and lung disease were the most serious side effects. In addition, almost 4% of patients who received this new drug died because of a fatal adverse reaction, mainly related to lung problems and infections.

Recommended For You
FDA NewsNewsworthyProstate Cancer
Erleada First Drug Approved for Patients with Nonmetastatic Prostate Cancer
On February 14, 2018, the FDA approved Erleada (apalutamide; from Janssen) for the treatment of patients with nonmetastatic, castration-resistant prostate cancer.
Breast CancerFDA NewsNewsworthy
Verzenio Approved as Initial Treatment for Metastatic Breast Cancer
The CDK4/CDK6 inhibitor Verzenio received a new indication, for use alone or in combination with an aromatase inhibitor, as initial therapy in women with HR-positive, HER2-negative advanced or metastatic breast cancer.
Last modified: October 5, 2017

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.